Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

An Open-label, Randomized, Cross-over, Multiple Dose, Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of DA-5207 Transdermal Delivery System in Healthy Adults

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Inclusion Criteria:

• Health Voulunterrs (Age : 19~55 years)
• Body Weight : Male≥55kg, Female≥50kg
• 18.5 ≤BMI≤ 25.0

Exclusion Criteria:

• Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption
• Allergy or Drug hypersensitivity
• Clinically significant Medical History
• AST, ALT > Upper Normal Range*1.25, eGFR<60mL/min/1.73m²
• Heavy alcohol intake (more than 210g/week)
• Heavy smoker (more than 10 cigarettes/day)
• Heavy caffeine intake